Recent 8-K filings for TTRX

• July 7, 2026, 8:05 AM ET other material materiality 0.85 positive item 7.01item 9.01

  Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial

  Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.

• June 1, 2026, 8:45 AM ET other material materiality 0.75 positive item 7.01item 9.01

  Turn Therapeutics GX-03 Phase 2 interim: 92.6% EASI-50 at 4 weeks; no SAEs

  92.6% of GX-03 subjects achieved EASI-50 at 4 weeks vs 65.2% vehicle; 70.4% achieved EASI-75.

• May 18, 2026, 8:15 AM ET leadership materiality 0.60 positive item 7.01item 9.01

  Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead

  Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.

• March 31, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt

  Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.

• March 24, 2026, 7:59 PM ET debt materiality 0.75 positive item 1.01item 2.03item 3.02item 7.01item 9.01 ◈ Debt Financings◈ Equity Issuances◈ Material Agreements

  Turn Therapeutics secures up to $25M growth capital loan from Avenue Capital Group

  Initial $7M tranche funded at closing; up to $18M additional available upon clinical and corporate milestones.

• January 12, 2026, 6:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Turn Therapeutics provides pipeline update; GX-03 Phase 2 data expected H1 2026, appoints Martin Dewhurst to board

  Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.

• November 13, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal

  Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.

• October 30, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Turn Therapeutics enters global supply, development, and license agreement with Medline

  Agreement covers development, manufacture, and commercialization of products using Turn's PermaFusion delivery platform.

• October 28, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01item 9.01

  Turn Therapeutics enters global supply and development pact with Medline for PermaFusion platform

  Turn grants Medline exclusive worldwide license to use Turn's 510(k) clearance for wound-care field-of-use.

• October 22, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Turn Therapeutics updates on GX-03 phase 2 eczema trial: 25% enrolled, topline 2026; $85M GEM facility

  Phase 2 trial of GX-03 (topical IL-36/IL-31 inhibitor) for moderate-severe eczema: ~25% of targeted sample completed, no safety concerns; topline results expected in 2026.

• October 2, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.03item 5.03item 5.02item 9.01 ◈ Governance Changes ×2

  Turn Therapeutics effects direct listing on Nasdaq; appoints two independent directors

  SEC declared effective S-1 for direct listing of up to 17,868,760 shares of common stock on Nasdaq Global Market.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

11 positive 0 negative 9 neutral

source · TTRX on sec.gov